Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676879 | 0.85 | BACE1 (0.56) | BACE1BACE2OPRD1 | |
| SCHEMBL31538481 | 0.83 | BACE1 (0.57) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL32672583 | 0.83 | OPRD1 (0.54) | BACE1BACE2OPRD1OPRM1CASP3 | |
| SCHEMBL31500682 | 0.82 | ENPEP (0.54) | OPRD1OPRM1CASP3CASP7IL1RN | |
| SCHEMBL2198060 | 0.82 | CASP3 (0.36) | BACE1BACE2CASP3CASP7 | |
| SCHEMBL31195269 | 0.81 | MME (0.50) | OPRD1OPRM1IL1RNERAP2 | |
| SCHEMBL29860725 | 0.81 | OPRM1 (0.53) | BACE1BACE2OPRD1OPRM1CASP3 | |
| SCHEMBL30123741 | 0.81 | BACE1 (0.59) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL2193224 | 0.80 | OPRM1 (0.50) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL30350510 | 0.80 | ACE (0.48) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100047762-A1 | METHOD TO MONITOR DRUG EFFICACY IN DIABETIC PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | BACE1 1760/4885BACE2 763/4885OPRD1 640/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | BACE1 4076/4885BACE2 2622/4885OPRD1 1163/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | BACE1 1708/4885BACE2 612/4885OPRD1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.